Table 1.
ADCs in MM
| Target | Agent | Active key trials (phase) | Prior lines | Regimen | Toxicities (≥ grade 3) |
|---|---|---|---|---|---|
| BCMA | Belantamab mafodotin | NCT03715478 (Ph I/II) | RRMM | + Pom/Dex | Keratopathy/MEC, ↓ VA, neutropenia, thrombocytopenia, lung infection, dyspnea |
| NCT03848845 DREAMM-4 (Ph II) | RRMM | + Pembrolizumab | - | ||
| NCT04126200 DREAMM-5 (Ph II) | 3 or more | +/− GSK3174998 or +/− GSK3359609 or +/− nirogacestat or +/− dostarlimab | - | ||
| NCT03544281 DREAMM-6 (Ph II) | RRMM | + Len/Dex or + Bor/Dex | Keratopathy/MEC, thrombocytopenia | ||
| NCT04484623 DREAMM-8 (Ph III) | 1 or more | + Pom/Dex | - | ||
| NCT04091126 DREAMM-9 (Ph III) | TI-NDMM | +/− Bor/Len/Dex | - | ||
| NCT04398745 DREAMM-12 (Ph I) | 2 or more | Single agent | - | ||
| NCT04177823 (Ph I) | 2 or more | Single agent | - | ||
| MEDI2228 | NCT03489525 | RRMM | Single agent | Thrombocytopenia, pleural effusion, rash, transaminitis | |
| AMG 224 | NCT02561962 (Ph I) | 3 or more | Single agent | Thrombocytopenia, transaminitis, fatigue, nausea, anemia | |
| CD38 (ADC) | TAK-169 | NCT04017130 (Ph I) | 2 or more | Single agent | - |
| TAK-573 | NCT03215030 (Ph I/II) | 3 or more | +/− Dex | - | |
| CD46 (ADC) | FOR46 | NCT03650491 (Ph I) | RRMM | Single agent | - |
| CD74 (ADC) | STRO-001 | NCT03424603 (Ph I) | RRMM | Single agent | - |
↓: decreased; -: not applicable; Ph: clinical trial phase; TI-NDMM: transplant-ineligible newly diagnosed MM; MEC: microcyst- like epithelial changes; VA: visual acuity